

# ASTRIA CONNECTION

HAE | Special Edition | August 2024

**NAVENIBART**



## EXCITING NEWS:

# STAR-0215 has a new generic name. Introducing...navenibart (nah-VEN-eh-bart)

## What is a generic name?

A generic name, also known as a United States Annotated Name (USAN) or an International Nonproprietary Name (INN), identifies a drug substance or ingredient. For example, Advil's generic name is ibuprofen.

On August 12, the Astria team shared that several organizations responsible for naming new drugs, including the World Health Organization and the American Medical Association, have adopted navenibart as the approved generic name for STAR-0215, our investigational medicine in clinical development for the treatment of HAE.

The prefix "nav-" represents Astria's commitment to navigate the development of a new potential treatment for people living with HAE with patients as our guiding stars. The infix "-eni-" represents "enzyme inhibitor" and the suffix "-bart" represents "monoclonal antibody."

In November 2021, the World Health Organization changed the naming convention for monoclonal antibodies. Monoclonal antibody names are now indicated with the suffix "-bart" rather than the previously used suffix "-mab." Generic drug names ending with "-bart" and "-mab" all represent monoclonal antibodies.



“We chose the prefix ‘nav-’ to symbolize navigating the development of navenibart with patients as our guiding stars. We are proud to share a generic name that reiterates our commitment to people living with HAE and ensuring their insights guide all of the work that we do.”

Chris Morabito, M.D.  
Chief Medical Officer at Astria

“Our vision for navenibart is to be a preventative treatment and make a meaningful difference in the lives of people living with HAE. We are grateful to the HAE community for their guidance and support in the development of navenibart.”

Jill C. Milne, Ph.D.  
Chief Executive Officer



## What does this mean for STAR-0215, clinical trial participants receiving STAR-0215, and the broader HAE community?

Even with its new name, STAR-0215 is the same product with no changes to what it is, how it is used, or its results to date, including safety and efficacy data from our clinical trials. Though you will see “navenibart” replace “STAR-0215” across Astria’s website, informational materials, news releases, etc., it is important to note that STAR-0215 remains the same. In short, navenibart is STAR-0215!

Our team is actively working to prepare for a global Phase 3 clinical trial of navenibart in people living with HAE. Information about trial locations and criteria to participate is expected to be available in the first quarter of 2025 (January through March).

## Stay in touch!

Want the latest Astria Connection sent straight to your inbox?  
Click [here](#) to subscribe.

For advocacy questions: [advocacy@astriatx.com](mailto:advocacy@astriatx.com)

Follow us on social media: [@AstriaTx](#)



The information provided here is for those affected by HAE and caregivers. Navenibart is in clinical development and not approved in any territory.

